Context: Though adequate luteal hormone production is essential for establishing pregnancy, luteal phase deficiency (LPD) is poorly characterized among eumenorrheic women.
been associated with abnormal estradiol (E2) and progesterone production, shortening of the menstrual cycle by shortening of the luteal phase, irregular menstrual bleeding (3, 4) , and pregnancy related disorders such as infertility and early pregnancy loss (5, 6) .
Diagnosis of LPD has historically been based on histologic evaluation of endometrial maturation, serum progesterone concentrations, and luteal phase duration assessed via basal body temperature (BBT) (3) . However, the diagnostic accuracy of endometrial histologic dating to assess LPD has been questioned, due to the normal interand intra-individual variation in endometrial maturation (7) , with an estimated positive predictive value (PPV) of Ͻ 10% (8) . Identification of suboptimal progesterone production is challenging and potentially unreliable as well. Progesterone concentrations peak 8 to 10 days after ovulation (4) . Consequently, appropriate timing of serum blood draws depends on identification of ovulation. Clinicians and researchers prefer timing ovulation based on urine luteinizing hormone (LH) for predicting day of ovulation and defining luteal length as it has been shown to have better accuracy than using BBT (3, 6, 9) .
The relevance of LPD as a distinct clinical entity has recently been debated, due in part to lack of a reliable test to diagnose (3, 4) . With BBT and endometrial histologic dating no longer considered reliable LPD diagnostic tools, further research using gold standard methods to time ovulation to determine luteal phase duration and repeated measurements of progesterone to assess normal vs pathologic luteal phase sufficiency are needed. While sporadic LPD may have limited clinical relevance, 28% of recurrent pregnancy losses are thought to be due to LPD (10) , highlighting the importance of proper management of LPD when consistently present. Managing recurrent pregnancy loss with targeted interventions has the potential to reduce adverse maternal and neonatal outcomes and healthcare spending (11, 12) .
The primary objective of this study was to evaluate whether LPD occurs in healthy, regularly menstruating women with no known gynecologic disorders. To carry out our objective, we evaluated the prevalence and overlap of short luteal phase duration and suboptimal luteal progesterone concentration (the most common clinical and biochemical definitions of LPD) in a prospective cohort of 259 premenopausal women enrolled in the BioCycle Study. Our secondary objective was to explore whether clinical and/or biochemical LPD are associated with cycle and phase-specific reproductive hormone profiles, including E2, LH, and follicle-stimulating hormone (FSH).
Materials and Methods

Study Population
The BioCycle Study was a prospective cohort of 259 women followed for one (n ϭ 9) or two (n ϭ 250) menstrual cycles (13) . Participants were recruited from healthy premenopausal volunteers aged 18 -44 years from the Western New York State. Women were included if they had a self-reported cycle length between 21 and 35 days during the past six months and had not used hormonal contraceptives during the past three months or been pregnant within the past six months. To be enrolled, women could not have ever sought infertility treatment or had any prior diagnosis of endometriosis, polycystic ovary disease, uterine fibroids (past twelve months), untreated gynecologic infection (past six months), or gynecologic surgery (past year). Additionally, women with a history chronic disease, an unwillingness to abstain from medications (including hormonal contraceptives), or a desire to start trying to conceive were excluded. The University at Buffalo Health Sciences Institutional Review Board (IRB) approved the study and served as the IRB designated by the National Institutes of Health under a reliance agreement. All participants provided written informed consent.
Hormone and Ovulation Assessment
Participants provided serum samples at up to eight clinic visits per cycle, with midcycle visits determined using the assistance of a fertility monitor (FM) (Clearblue ® Easy Fertility Monitor, Inverness Medical, Waltham, MA, USA) (9) . Clinic visits were aimed to correspond to biologically relevant windows including menstruation, midand late-follicular phase, LH/FSH surge, ovulation, and early-, mid-, and late-luteal phase. FMs measured estrone-3-glucuronide (E3G) and LH in first morning urine, starting on day six after the first day of menses and continuing for 10 -20 days, depending on the timing of the LH surge. FM data were downloaded to obtain daily E3G and LH values for each participant. Participants were highly adherent to the study protocol, with 96% and 93% of women bringing in their FM to have data downloaded for cycles one and two, respectively, and 94% of all women completing at least seven clinic visits per cycle.
E2, progesterone, LH, and FSH were measured in serum collected at each clinic visit. Fasting morning blood samples were processed according to standardized protocols (14) . Samples were stored frozen at -80°C and sent as complete participant cycle batches to Kaleida Health Center for Laboratory Medicine (Buffalo, NY) for analysis of hormone concentrations. Total E2, progesterone, LH and FSH were measured via IMMULITE ® 2000 Solid Phase Competitive Chemiluminescent Enzymatic Immunoassay. Coefficients of variation reported by the laboratory were Ͻ 10% for E2, Ͻ5% for LH and FSH, and Ͻ 14% for progesterone.
Progesterone generally remains below 1 ng/mL (1 ng/mL ϭ 3.18 nmol/L) in the follicular phase, rises to above 1 ng/mL during the peri-ovulatory period, and rises steadily thereafter until its decline over the days preceding menses (14) . While progesterone Ͼ 3ng/mL is indicative of ovulation, concentrations below this have been found to occur in ovulating women with apparently normal endometrial maturation (2, 14) . Consequently, we defined ovulatory cycles as any cycle with progesterone Ͼ 1 ng/mL, which had a urine or serum LH surge prior to the midluteal visit.
Menses Assessment
Participants recorded menstrual bleeding (yes/no) via a daily diary. Menses length was defined as a bleeding episode that included Ͼ 2 days of bleeding preceded by at least two bleed-free days (15, 16) . We specified premenstrual spotting as Յ 2 days of bleeding that were preceded and followed by at least two recorded bleed-free days. Only 2% of diary days were missing information on the presence or absence of any menstrual bleeding. If participants reported any menstrual bleeding on a given day, they were instructed to complete a detailed follow-up menstrual flow questionnaire consisting of pictograms that assessed quantity, size, and observed amount of blood loss for each feminine product used, as well as any extraneous blood loss not captured by sanitary protection (17) . Total blood loss on each bleeding day was estimated using an algorithm (17, 18) .
Covariate Assessment
At study enrollment, anthropometric measures including height and weight were obtained using standardized protocols. At the end of the follow-up period, percent body fat was measured using duel energy X-ray absorptiometry (DEXA) scans (Holigic Discovery Elite, software version 12.4.1, Waltham, Massachusetts) (13) . Age, self-identified race, smoking status, and reproductive history were obtained using baseline questionnaires (13) . Daily minutes of vigorous exercise were captured via the daily diary. Participants completed a 24-hour dietary recall at the clinic during the four visits corresponding to menstruation, midfollicular phase, ovulation and midluteal phase from which total energy intake was calculated using the Nutrition Data System for Research (NDSR, 2005, Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN).
Statistical Analyses
We restricted analyses to ovulatory cycles where total cycle length was not missing. Previous work has shown ovulation to occur on the day after the FM peak (ie, urine LH surge) in most cycles (19) . Consequently, day of ovulation was assigned using the day of the urine LH surge from the FM, or the day of the serum LH maximum value when FM data were not available, plus one day.
Cycle length was calculated as the number of days between the first day of menstrual bleeding and the onset of the next menses for each cycle. Duration of the follicular phase was calculated as the number of days between the first day of menstrual bleeding and day of ovulation; and luteal length was calculated as the day after ovulation through the day prior to the onset of menses. To ensure that serum samples were compared within the same biologically relevant windows between women, we set day of ovulation as day zero and then aligned cycle visits as plus or minus days relative to ovulation.
Our diagnostic criteria for LPD included short luteal phase duration, defined as Ͻ 10 days (clinical LPD) (6, 20, 21) , and low luteal progesterone concentrations, defined as maximum luteal level Յ 5 ng/mL (biochemical LPD) (22, 23) . We evaluated the number of cycles and women who met clinical and/or biochemical LPD criteria. We additionally assessed the number of cycles and women who had 1) a more liberal definition of low luteal progesterone concentration (defined as maximum luteal level Յ 10 ng/mL) (23, 24) ; and 2) a luteal phase duration of Ͻ 9 or Ͻ 11 days (25, 26) .
Descriptive statistics were calculated for demographic, lifestyle, and menstrual cycle characteristics for clinical and biochemical LPD, respectively. Generalized linear models were used to determine significant differences between groups. Linear mixed models on the log scale of hormones were used to evaluate the association between clinical and biochemical LPD, respectively, on follicular and luteal E2, LH, and FSH and luteal progesterone concentrations. Random-intercept, repeated-measurement models were used to account for the variation between baseline concentration of hormones in individual women and the correlation between cycles of the same women. Since short luteal phase duration was our primary clinical diagnostic criterion, all luteal hormonal analyses were restricted to Յ 8 days post ovulation.
To evaluate integrated hormone concentrations, we calculated the area-underthe-curve (AUC) for each cycle and hormone. We assumed an approximately linear relationship between hormone concentration values between visits and calculated the area under each trapezoid between visits. Mean AUCs were then compared by clinical and biochemical LPD using generalized linear models.
Multivariable models were adjusted for age, race, and percent body fat. Alternative models that adjusted for parity, smoking, physical activity, and total energy intake did not appreciably alter the estimates (data not shown). All analyses were repeated using a more stringent definition of an ovulatory cycle (ie, luteal progesterone Ͼ 3ng/mL). Analyses were conducted in SAS, version 9.3 (SAS Institute, Cary, NC).
Results
Among the 476 cycles with menstrual cycle length information, there were 13 cycles (2.7%) considered anovulatory, based on luteal progesterone Ͻ 1ng/mL, and excluded from our analyses. Of the 463 ovulatory cycles, there were 41 (8.9%) cycles with clinical LPD, 39 (8.4%) cycles with biochemical LPD, and 20 cycles (4.3%) meeting both criteria. While most women experienced either clinical or biochemical LPD for only one cycle, there were 8 (3.4%) women who experienced two clinical LPD cycles and 5 (2.1%) women who experienced two biochemical LPD cycles. Nearly all cycles with clinical LPD also had peak luteal progesterone Յ 10 ng/mL (n ϭ 38 cycles, 8.2%), but of the 422 cycles without clinical LPD, roughly one-third (n ϭ 132, 31.3%) also had progesterone Ͻ 10.0 ng/mL (Figure 1) . The alternative short luteal phase duration cut-points showed that 29 (6.3%) cycles among 14 women had luteal phase Ͻ 9 days and 69 (14.9%) cycles among 39 women had luteal phase Ͻ 11 days.
Women with either clinical or biochemical LPD were more likely to be younger, nulliparous, with lower percent body fat, and lighter menses compared to women without LPD (all P Յ .05) ( Table 1) . Additionally, women with clinical LPD were more likely to be white (82.9% vs. 58.5%, P ϭ .02), with shorter cycle lengths (26.6 vs. 29.0 days, P Ͻ .001) while women with biochemical LPD were less likely to be married (2.6% vs. 29.7%, P ϭ .01), more likely to be sexually inactive (66.7% vs 44.8%, P ϭ .03), and have longer cycle lengths (30.4 vs. 28.6 days, P ϭ .02). Of the 11 cycles with reported premenstrual spotting, one had clinical LPD (P ϭ 1.0) and none had biochemical LPD (P ϭ .61).
After adjusting for age, race, and percent body fat, women with clinical LPD had lower log E2 concentrations during the follicular (␤ϭ-0.26, 95% CI: -0.41, -0.10; P ϭ .001) and luteal (␤ϭ-0.18, 95% CI: -0.33, -0.02; P ϭ .03) phases; lower progesterone during the luteal phase (␤ϭ-0.26, 95% CI: -0.51, 0.00; P ϭ .05); lower LH during the follicular (␤ϭ-0.26, 95% CI: -0.41, -0.11; P Ͻ .001) and luteal (␤ϭ-0.38, 95% CI: -0.53, -0.22; P Ͻ .001) phases; and lower FSH during the follicular (␤ϭ-0.13, 95% CI: -0.22, -0.04; P ϭ .001) and luteal (␤ϭ-0.30, 95% CI: -0.42, -0.17; P Ͻ .001) phases compared to women without clinical LPD (Figure 2) . Similarly, after adjustment, women with biochemical LPD had significantly lower log E2 during the follicular (␤ϭ-0.44, 95% CI: -0.58, -0.29; P Ͻ .001) and luteal (␤ϭ-0.19, 95% CI: -0.35, -0.03; P ϭ .02) phases; lower progesterone (as expected due to definition) during the luteal phase (␤ϭ-0.63, 95% CI: -0.89, -0.37; P Ͻ .001); but no significant differences in LH or FSH concentrations during either the follicular or luteal phases compared to women without biochemical LPD (Figure 2) .
In addition, women with clinical LPD compared to those without had lower E2 (P Ͻ .001), progesterone (P Ͻ .001), LH (P ϭ .01), and FSH (P ϭ .03) integrated hormone levels via AUC analysis across the cycle after adjusting for age, race, and percent body fat (Table 2) . Women with biochemical LPD had lower E2 (P ϭ .001) and progesterone (P Ͻ .001) but higher LH (P ϭ .04) integrated hormone levels after adjustment compared to women without biochemical LPD. We found similar results for all our analyses when we restricted our sample to ovulatory cycles where at least one luteal progesterone was Ͼ 3ng/mL (n ϭ 443, data not shown).
Discussion
Our findings suggest that regularly menstruating women do express evidence of subtle menstrual cycle disorders manifested as LPD. We found that short luteal phase duration, defined as less Ͻ 10 days, or suboptimal luteal progesterone, defined as Ͻ 5ng/mL maximum progesterone (primary clinical and biochemical diagnostic criteria) affected 8.9% and 8.4% of ovulatory cycles, respectively, among study participants, with 4.3% of cycles meeting both criteria. Extending the biochemical criterion to maximum serum luteal progesterone Ͻ 10 ng/mL (23) resulted in greater overlap with clinical LPD but, as a diagnostic criterion alone, would result in a higher false positive rate of LPD as supported by previous research (2). While clinical and biochemical LPD share certain characteristics and some of the same associated risk factors, the lack of complete consistency in regards to menstrual cycle characteristics and reproductive hormone concentrations indicates that these two types of LPD may act through different mechanisms.
Among normal cycling women, the prevalence of a luteal phase duration of Ͻ 9 and Ͻ 11 days (relative to ovulation), respectively, have been estimated to be 5.2% (27) and 8.0% (28) . We found similar results with 5.1% of women experiencing a luteal phase duration of Ͻ 9 days and 12.4% of women experiencing a luteal phase duration of Ͻ 11 days. While early studies on LPD report consistency between a short luteal phase duration and suboptimal progesterone levels (29, 30) , these studies were small and relied on BBT to identify ovulation and therefore calculate luteal phase duration. In a more recent study conducted among normal cycling women with daily serum hormone assessment, the authors found that short luteal phase duration is a poor predictor of luteal integrated progesterone levels (24) . A larger study (n ϭ 335 cycles), which collected daily serum samples to identify ovulation, showed that up to half of cycles with short luteal phase duration, defined as Ͻ 11 days, had adequate luteal serum progesterone measured ϩ5 to ϩ7 days post-LH surge (28) . Likewise, we found that over half of the cycles with short luteal phase duration had Ͼ 5ng/mL peak luteal progesterone levels. Identification of a short luteal phase (Ͻ10 days) via ovulation detection through validated instruments may serve as the least invasive and most accurate tool for assessing short luteal phase duration. Obtaining a serum progesterone level of Ͻ 10 ng/mL approximately 6 to 8 days postovulation may provide additional confidence that a cycle can be categorized with LPD. While any luteal phase progesterone concentration Ͼ 3 ng/mL provides reliable evidence of ovulation (2); no consistent threshold has been established to identify abnormal corpus luteum function (15) , thus supporting the growing body of evidence indicating that serum progesterone alone lacks specificity for diagnosing LPD (9, 15) . Moreover, more invasive procedures such as endometrial biopsy have proven to be invalid diagnostic tools for LPD assessment (2, 3).
Repeated measures analyses (taking into account multiple cycles from the same woman) used to assess associations between demographic, lifestyle, diet, and menstrual cycle characteristics. Mean Ϯ SD unless otherwise noted. 1 International System of Units (SI) conversion for progesterone: 1 ng/mL ϭ 3.18 nmol/liter.
2 Sexual activity was defined as vaginal intercourse. Figure 2 . Geometric mean concentration of reproductive hormones (A, estradiol; B, progesterone; C, LH; D, FSH) among ovulatory women (n ϭ 237 women, 463 cycles) by luteal phase deficiency category (normal, triangle; luteal duration Ͻ 10 days in length, circle; Յ 5 ng/mL luteal progesterone for all measured levels, square). Day of estimated ovulation was set to day 0. Menses: Ͻ-8 days; Follicular: -7 Յ day Յ -3; Ovulation (3 visits: day -2, -1, and 0); Early Luteal: ϩ1 Յ day Յ ϩ3; Mid Luteal: ϩ4 Յ day Յ ϩ8. We restricted analyses to Յ ϩ8 days post ovulation since short luteal phase duration was our primary clinical diagnostic criteria and no woman with short luteal phase duration came in for a serum sample Ͼ ϩ8 days. P-values represent significant differences between reproductive hormone concentrations for clinical (luteal phase duration Ͻ 10 days) and biochemical (luteal progesterone Յ 5 ng/mL) luteal phase deficiency compared to normal cycles after adjusting for age, race, and percent body fat (ns, nonsignificant). International System of Units (SI) conversion, estradiol: 1 pg/mL ϭ 3.67 pmol/L; progesterone: 1 ng/mL ϭ 3.18 nmol/L; LH: 1 ng/mL ϭ 4.34 mIU/L; FSH 1 mIU/ml ϭ 1 IU/L.
In the present study, both clinical and biochemical LPD were associated with decreased blood flow at menses. While a previous study found an association between lighter bleeding and anovulation (28) , our finding of lighter bleeding associated with LPD is, to our knowledge, novel. This finding is physiologically plausible since the thickening and maturation of the uterine endometrium throughout the menstrual cycle is highly dependent on estrogen secretion during the follicular phase and on progesterone support in the luteal phase, which were both lower in cycles with LPD (defined either clinically or biochemically) in our study.
In contrast to menstrual flow, we found inconsistent results in regards to LPD criteria and cycle length. In corroboration with previous studies (30, 31) , we found shortened luteal duration to be associated with shortened total cycle length. Conversely, we found biochemical LPD to be associated with longer total cycle length. Whether our finding lends credence to the hypothesis that LPD may result from more than one pathologic mechanism or is a result of missed peak progesterone assessments is not clear. Polycystic ovary syndrome (PCOS), an independent endocrine disorder but sharing a common pathophysiological profile with LPD (33) , has been shown to be associated with longer cycles (Ͼ35 days days) (33) . It has been speculated that LPD may be involved in the infertility observed among women with polycystic ovary syndrome, emphasizing the potential overlap of these gynecologic disorders (32) . However, despite adequate luteal phase visits among biochemical LPD cycles (mean ϭ 2.4), there was variability in the days postovulation that sera were collected, warranting further research to confirm our findings.
We found both follicular and luteal E2 concentrations to be significantly lower in women with clinical and/or biochemical LPD, which is in agreement with two previous studies among regularly-menstruating women (26, 28) . Only one previous study assessed LH and FSH levels among eumenorrheic women, reporting lower midfollicular FSH in women with luteal phase duration Ͻ 10 days compared with controls, but no difference in LH levels (30) . In contrast, we found significantly lower LH and FSH across the cycle for women with luteal phase duration Ͻ 10 days compared to cycles Ն 10 days. Reasons for discrepant findings may be due to the previous study's small sample size (n ϭ 11 cycles among 4 women) and use of BBT to assess ovulation. Our finding of reduced follicular LH and FSH for clinical LPD supports the hypothesis that alterations of the hypothalamic-pituitary-ovarian axis impair both folliculogenesis and (indirectly or directly) subsequent corpus luteum function, which may ultimately compromise endometrial maturation and stability. Our findings of higher LH for biochemical LPD via the AUC analysis supports the idea that clinical and biochemical LPD potentially act through different mechanisms. Previous research indicates that ovulatory women with PCOS have increased GnRH pulsatility over the entire cycle, leading to increased LH production, yet still have a deficient luteal phase progesterone secretion suggesting ovarian dysfunction (33) .
The BioCycle Study had several strengths including intensive monitoring of a large number of women with no known reproductive or gynecologic disorders over the course of two menstrual cycles. Additionally, we used a validated FM to time clinic visits so that serum samples would be drawn at biologically relevant windows, pro- Mean area under the curve were compared by LPD status (yes/no) using repeated measures analyses, adjusting for woman's age, race, and percent body fat.
doi: 10.1210/jc.2013-3534 jcem.endojournals.orgviding a superior measurement for identifying ovulation compared with BBT. Nevertheless, our study had several limitations including an inability to obtain daily biospecimen measurements or assess ovulation via ultrasound because of cost restrictions. Consequently, we may have incorrectly classified some of the suboptimal luteal progesterone cycles, due to a missed midluteal visit, or some of the short luteal phase duration cycles, due to failure of the FM to correctly identify peak fertility. However, we thoroughly reviewed FM data for the urine LH surge, and used serum LH measurements in combination with urine LH measurements to minimize any potential misclassification. Finally, we were not able to assess whether LPD is associated with aneuploid oocytes. However, given the evidence of treatment efficacy for progesterone supplementation in women with Ն 3 pregnancy losses (34), karyotypic abnormalities associated with ovulation are not likely to be the predominant cause of LPD, at least among women with recurrent LPD. Given our finding that short luteal phase duration Ͻ 10 days in combination with maximum luteal progesterone Յ 10 ng/mL revealed the best overlap between clinical and biochemical LPD, clinicians and researchers wishing to assess LPD may find that a validated ovulation prediction kit in combination with a well-timed progesterone serum sample (ie, ϩ 6 to ϩ 8 days post ovulation) is a costeffective and reasonably accurate means to assess LPD. Since it is well known that implantation occurs within a narrow window of the midluteal phase and that delayed implantation predisposes a woman to infertility and/or pregnancy loss, further population-based research examining whether well-diagnosed LPD is associated with implantation delay is warranted. Additionally, studies looking at treatment efficacy (35) should be re-evaluated using improved diagnostic tools. In summary, our findings suggest that women with regular menstrual cycles do express evidence of subtle menstrual cycle disorders manifested as LPD based on luteal length or level of progesterone secretion, potentially through different mechanisms (32) . We also found that both types of LPD are highly associated with hormonal differences in both the follicular and luteal phase, suggesting that luteal deficiency may in fact be a manifestation of follicular deficiency affecting all subsequent phases of the menstrual cycle (1, 26) . Additional research is needed to assess the clinical implications of both types of LPD.
